At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 21 enrolled
Drug / intervention
Olanzapine +5 moredrug
Likely dose
Olanzapine 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of Optimal Antipsychotic Treatments for Schizophrenia Pilot Study
In Brief
A Phase 4 clinical trial evaluating Olanzapine, Perphenazine, and 4 other interventions for Schizophrenia. Completed, enrolled 21 participants across 13 sites.
Detailed Summary
This study will compare the safety and effectiveness of three different antipsychotic medications, as well as the use of other medications to limit treatment side effects, in adults with schizophrenia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2008
First PostedDec 2008
Primary CompletionSep 2009
Study CompletionOct 2009
TodayJul 2026
First PostedDec 4, 2008
Enrollment StartDec 1, 2008
Primary CompletionSep 1, 2009
Study CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 17.6 years ago
Interventions
Olanzapinedrug
Daily tablets of 10 to 30 mg
Perphenazinedrug
Daily tablets of 8 to 24 mg
Aripiprazoledrug
Daily tablets of 10 to 30 mg
Metformindrug
Daily tablets of 850 to 2550 mg
Simvastatindrug
Daily tablets of 20 to 40 mg
Benztropinedrug
Daily tablets of 1 to 2 mg